Saturday 17 October 2026
Export VINC’s income statement to Excel — free account
Vincerx Pharma, Inc.
VINC Healthcare Biotechnology
In the quarter to March 2025, EPS grew 87.9% and free cash flow grew 42.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.02
0.01
−33.33%
Follow VINC
| Mar '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
| (3,136.43%) | (431.29%) | (217.55%) | (142.45%) |
+8 more TTM periods Free account |
|
| (287.21%) | (229.38%) | (131.14%) | (99.27%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,096.08%) | (2,663.77%) | (421.75%) | (216.06%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(6.38) | (13.77) | (12.25) | (14.73) | |
Free Cash Flow |
(22.84) | (26.13) | (27.96) | (28.23) | |
| Other line items | |||||
Cash ROIC |
(346.88%) | (335.39%) | (145.05%) | (88.64%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.01 | 0.87 | 1.03 | 1.00 | |
Depreciation/Fixed assets |
— | 0.00 | 10.14 | 4.24 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.38) | (13.77) | (12.25) | (14.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates